Studies – Uptown Research Institute

Major Depressive Disorder (MDD): Outpatient

Purpose of this Study: To compare the study drug to placebo as an add on to antidepressant therapy for treatment in adults with MDD.

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Length of Study: Approximately one year.

Qualified Study Participants Will Receive:

Study-related care and office visits at no cost
Investigational study medication at no cost
$50 compensation per visit

Am I Eligible for the Study?

Aged 18 - 65 years old
Diagnosed with MDD and experiencing a current major depressive episode of ≥ 8 weeks in duration
Have taken antidepressants during current episode but are still struggling with the symptoms of depression
Medically stable with a stable living residence

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? All new medicines are tested in clinical trials. You may also help others by advancing science, and you may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back and will conduct a short phone screen to determine if you should visit our office for further evaluation.

[/expand]

Bipolar Depression: Outpatient

Purpose of this Study: This study examines if a new medication is safe and effective in treating patients with Bipolar disorder who are currently depressed.

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Design of Study: This is an outpatient study and all participants will receive either the study medication or a placebo. Participants on Depakote or Lithium may stay on these medications throughout the study.

Length of Study: Nine (9) visits over 10 weeks.

Qualified Study Participants Will Receive:

Study-related care and office visits at no cost
Medication at no cost
$75 compensation per visit

Am I Eligible for the Study?

Aged 18 - 65 years old
Diagnosis of Bipolar Disorder
Current depressive episode lasting from 2 weeks to 6 months
Medically stable with a stable living residence

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? Clinical trials are how all new medicines are tested. These trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. You may also help others by advancing science and may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

[/expand]

Negative Symptoms of Schizophrenia: Outpatient & Inpatient

Purpose of this Study: This study examines the safety and effectiveness of the study drug, as compared to placebo, in adults with negative symptoms of schizophrenia. Negative symptoms include flat affect, apathy, inability to feel pleasure, reduced social drive, loss of motivation, and lack of social interest.

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Length of Study: One year, which is primarily outpatient but does include a 2-4 night inpatient period at both the beginning and end of the first 12 weeks.

Qualified Study Participants Will Receive:

Study-related care and office visits at no cost
Medication at no cost
$75 compensation per outpatient visit; $100 compensation per inpatient visit

Am I Eligible for the Study?

Aged 18 - 55 years old
Primary diagnosis of schizophrenia for at least one year
Currently experiencing negative symptoms
Medically stable with a stable living residence

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? All new medicines are tested in clinical trials. You may also help others by advancing science, and you may gain access to a new treatment.

[/expand]

Extended-release Injection Treatment for Schizophrenia: Outpatient

Purpose of this Study: This study is being conducted to evaluate the efficacy, safety, and tolerability of different doses and durations (one month or two months) of risperidone given by injection as compared to placebo (no active ingredient) for use as a potential maintenance treatment in adults with schizophrenia. This study hopes to determine if the study drug prevents the worsening of the signs and symptoms of schizophrenia

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Design of Study: This is a randomized, double-blind, placebo-controlled study.

Length of Study: The total study duration for a subject will be approximately one year with the possibility of continuing on the same medication in a follow-up open-label study.

Qualified Study Participants Will Receive:

Study-related care and office visits at no cost
Medication at no cost
$75.00 per completed office visit; $30 per completed telephone visit

Am I Eligible for the Study?

Aged 18 - 65 years old
Diagnosed with schizophrenia
Has been responsive to an antipsychotic treatment (other than clozapine) in the past year
Willing to take “add-on” medication
Medically stable with a stable living residence

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

Receive the newest and latest treatments in psychiatry.
Help yourself and others by contributing to medical research.
Receive study-related care and medication at no cost to you or your insurance provider.
Financial compensation for participation.
Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial.

Interested in Participating? If you are interested in joining this study, please click on the “Sign Up” button below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back conduct a short phone screen to determine if you should visit our office for further evaluation.

Improving Cognition in Schizophrenia: Outpatient

Purpose of this Study: This study is being conducted to evaluate if the study drug may improve ability to remember, think clearly, and/or solve problems (cognitive skills) when taken with regular antipsychotics.

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Design of Study: This is a randomized, double-blind, placebo-controlled study. All participants remain on their baseline antipsychotic.

Length of Study: The total study duration for a subject will be approximately 20 weeks.

Qualified Study Participants Will Receive:

Study-related care and office visits at no cost
Medication at no cost
$75.00-$150 per completed office visit; $25 per completed telephone visit

Am I Eligible for the Study?

Aged 18-50 years old, male or female
Primary diagnosis is schizophrenia, with no hospitalization within 3 months
Medically stable with stable residence
Willing to take an add on medication
Must identify a support person to act as an informant as needed (this person interacts with patient at least twice weekly)

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

Receive the newest and latest treatments in psychiatry.
Help yourself and others by contributing to medical research.
Receive study-related care and medication at no cost to you or your insurance provider.
Financial compensation for participation.
Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial..

Long-acting Injection Treatment for Schizophrenia

Purpose of this Study: This study is being conducted to evaluate the bioequivalence of the study drug compared with Invega Sustenna. It is expected to have similar efficacy and safety compared with Invega Sustenna, and to be a cost saving treatment since schizophrenia and schizoaffective disorder require continuous and long-term therapy with antipsychotics.

[expand title="Learn more and Sign Up for this Study" swaptitle="Close"]

Design of Study: This is a randomized, double-blind, bioequivalence study. There will be three study treatment periods to allow for crossover of study product and reference product. Each treatment period will have three doses of test or reference product each.

Length of Study: The total study duration will be approximately 22 months, including a screening period of up to 28 days and three 12-week (84 days) treatment periods.

Qualified Study Participants Will Receive:

Study-related care, inpatient care, and office visits at no cost.
Investigational study medication at no cost.
$75 compensation per visit.
Free transportation to and from appointments.

Am I Eligible for the Study?

Aged 18 to 64 years
Diagnosed with Schizophrenia or Schizoaffective Disorder
Have an identified reliable caregiver
Medically stable with a stable living residence

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

Receive the newest and latest treatments in psychiatry.
Help yourself and others by contributing to medical research.
Receive study-related care and medication at no cost to you or your insurance provider.
Financial compensation for participation.
Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial.